statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024 Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024 PR Newswire...

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

Haemonetics Receives FDA Clearance for New TEG 6s Global Hemostasis - HN Cartridge Haemonetics Receives FDA Clearance for New TEG 6s Global Hemostasis - HN Cartridge PR Newswire BOSTON, April 4, 2024...

Haemonetics Receives FDA Clearance for New TEG 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation Completes Acquisition of Attune Medical Haemonetics Corporation Completes Acquisition of Attune Medical PR Newswire BOSTON, April 1, 2024 BOSTON, April 1, 2024 /PRNewswire...

Haemonetics Corporation Completes Acquisition of Attune Medical

Haemonetics Co. (NYSE:HAE - Free Report) - Stock analysts at Zacks Research raised their Q1 2025 earnings estimates for shares of Haemonetics in a report issued on Thursday, March 28th. Zacks...

Q1 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Lifted by Zacks Research

Haemonetics Co. (NYSE:HAE  Free Report)  Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for Haemonetics in a research note issued on Thursday, March 28th. Zacks...

Haemonetics Co. Expected to Post Q1 2025 Earnings of $0.94 Per Share (NYSE:HAE)

After reaching an important support level, Haemonetics (HAE) could be a good stock pick from a technical perspective. HAE surpassed resistance at the 200-day moving average, suggesting a long-term...

Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors

In trading on Thursday, shares of Haemonetics Corp. (HAE) crossed above their 200 day moving average of 84.80, changing hands as high as 84.82 per share...

Bullish Two Hundred Day Moving Average Cross - HAE

This is a signal that HAE's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Haemonetics (HAE, $84.09) RSI Indicator left the overbought zone on March 27, 2024

Haemonetics (HAE, $81.64) RSI Indicator left the overbought zone on March 26, 2024

Haemonetics (HAE, $81.82) RSI Indicator left the overbought zone on March 25, 2024

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Volume	749,023.00
52-Wk High	$95.26
52-Wk Low	$70.74

HAE Haemonetics Corp.

About

Feed

News

Sentiment

Earnings

Fundamentals